Download PDF
Fortschr Neurol Psychiatr 2021; 89(03): 103-113
DOI: 10.1055/a-1244-2612
Übersicht

Narkolepsie im Erwachsenenalter: Definition, Ätiologie und Behandlung

Narcolepsy in adults: Definition, etiology and treatment
Michael Malter
1   Universität Köln, Klinik und Poliklinik für Neurologie
,
Janina Neuneier
1   Universität Köln, Klinik und Poliklinik für Neurologie
,
Annika Triller
2   Zentrum für Narkolepsie/Hypersomnien, Klin. Schlaf- und Neuroimmunologie, Institut für Immunologie, Universität Witten/Herdecke
,
Ulf Kallweit
2   Zentrum für Narkolepsie/Hypersomnien, Klin. Schlaf- und Neuroimmunologie, Institut für Immunologie, Universität Witten/Herdecke
› Author Affiliations
› Further Information
   Permissions and Reprints

Zusammenfassung

Narkolepsie ist eine Hypersomnolenz-Erkrankung, die mit einer Störung der Wach-Schlaf-Regulation einhergeht. Leitsymptome sind exzessive Tagesschläfrigkeit und Kataplexien. Zudem treten hypnagogene/hypnopompe Halluzinationen, Schlaflähmungen und gestörter Nachtschlaf auf. Es werden zwei Formen unterschieden. Bei der Narkolepsie Typ 1, früher Narkolepsie mit Kataplexie, besteht eine Hypocretin-Defizienz. Die Ursache der Narkolepsie Typ 2, früher Narkolepsie ohne Kataplexie, ist im Wesentlichen ungeklärt. Zur Diagnosestellung ist ein multimodaler Ansatz notwendig. Die Latenz zwischen Erkrankungsbeginn und Diagnosestellung in Europa beträgt im Mittel 14 Jahre. Es bestehen erhebliche Probleme in der Versorgung von Menschen mit Narkolepsie. Die in aller Regel lebenslange Behandlung der Narkolepsie umfasst sowohl nichtmedikamentöse Strategien als auch die symptomatische medikamentöse Behandlung.

Abstract

Narcolepsy is a hypersomnolence disorder of central origin that presents with a disturbance of the wake-sleep regulation. Lead symptoms consist of excessive daytime sleepiness and cataplexy. Nowadays, two types of narcolepsy are distinguished. Type 1 narcolepsy, formerly known as narcolepsy with cataplexy, is based on hypocretin deficiency. The cause of type 2 narcolepsy, formerly known as narcolepsy without cataplexy, remains mainly unknown. A multimodal approach is necessary for diagnosis. The mean latency between the onset of disease and diagnosis in Europe ranges 14 years. Narcolepsy has a major impact on workability and quality of life. The management of narcolepsy is usually life-long and includes non-pharmacological approaches and a symptomatic pharmacological treatment.

Schlüsselwörter

Narkolepsie - Hypocretin - Solriamfetol - Pitolisant - Methylphenidat - Natrium-Oxybat

Keywords

Narcolepsy - Hypocretin - Solriamfetol - Pitolisant - Methylphenidate - Sodium oxybate


Publication History

Received: 26 June 2020

Accepted: 17 August 2020

Article published online:
18 December 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • Literatur

  • 1 Scammel TE. Clinical features and diagnosis of narcolepsy in adults. wwwuptodatecom UpToDate, Wolters Kluwer: Wolters Kluwer; 2020
    Google Scholar
  • 2 Luca G, Haba-Rubio J, Dauvilliers Y. et al. Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: A European Narcolepsy Network study. J Sleep Res 2013; 22: 482-495
    CrossrefPubMedGoogle Scholar
  • 3 Latorre D, Kallweit U, Armentani E. et al. T cells in patients with narcolepsy target self-antigens of hypocretin neurons. Nature 2018; 562: 63-68
    CrossrefPubMedGoogle Scholar
  • 4 Luo G, Ambati A, Lin L. et al. Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy. Proc Natl Acad Sci U S A 2018; 115: E12323-E12332
    PubMedGoogle Scholar
  • 5 Ruoff C, Rye D. The ICSD-3 and DSM-5 guidelines for diagnosing narcolepsy: Clinical relevance and practicality. Curr Med Res Opin 2016; 32: 1611-1622
    CrossrefPubMedGoogle Scholar
  • 6 Khatami R, Luca G, Baumann CR. et al. The European Narcolepsy Network (EU-NN) database. J Sleep Res 2016; 25: 356-364
    CrossrefPubMedGoogle Scholar
  • 7 Bassetti CLA, Adamantidis A, Burdakov D. et al. Narcolepsy - clinical spectrum, aetiopathophysiology, diagnosis and treatment. Nat Rev Neurol 2019; 15: 519-539
    CrossrefPubMedGoogle Scholar
  • 8 Roth T, Dauvilliers Y, Mignot E. et al. Disrupted nighttime sleep in narcolepsy. J Clin Sleep Med 2013; 9: 955-965
    CrossrefPubMedGoogle Scholar
  • 9 Pizza F, Tartarotti S, Poryazova R. et al. Sleep-disordered breathing and periodic limb movements in narcolepsy with cataplexy: A systematic analysis of 35 consecutive patients. Eur Neurol 2013; 70: 22-26
    CrossrefPubMedGoogle Scholar
  • 10 Cohen A, Mandrekar J, St Louis EK. et al. Comorbidities in a community sample of narcolepsy. Sleep Med 2018; 43: 14-18
    CrossrefPubMedGoogle Scholar
  • 11 Ruoff CM, Reaven NL, Funk SE. et al. High rates of psychiatric comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study of 9,312 patients in the United States. J Clin Psychiatry 2017; 78: 171-176
    CrossrefPubMedGoogle Scholar
  • 12 Hublin C, Kaprio J, Partinen M. et al. The prevalence of narcolepsy: An epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994; 35: 709-716
    CrossrefPubMedGoogle Scholar
  • 13 Silber MH, Krahn LE, Olson EJ. et al. The epidemiology of narcolepsy in Olmsted County, Minnesota: A population-based study. Sleep 2002; 25: 197-202
    CrossrefPubMedGoogle Scholar
  • 14 Scheer D, Schwartz SW, Parr M. et al. Prevalence and incidence of narcolepsy in a US health care claims database, 2008-2010. Sleep 2019 42.
    Google Scholar
  • 15 Oberle D, Drechsel-Bäuerle U, Schmidtmann I. et al. Incidence of Narcolepsy in Germany. Sleep 2015; 38: 1619-1628
    CrossrefPubMedGoogle Scholar
  • 16 Dauvilliers Y, Montplaisir J, Molinari N. et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001; 57: 2029-2033
    CrossrefPubMedGoogle Scholar
  • 17 Rocca FL, Pizza F, Ricci E. et al. Narcolepsy during childhood: an update. Neuropediatrics 2015; 46: 181-198
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Sakurai T, Amemiya A, Ishii M. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998; 92: 1 page following 696
    CrossrefPubMedGoogle Scholar
  • 19 de Lecea L, Kilduff TS, Peyron C. et al. The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998; 95: 322-327
    CrossrefPubMedGoogle Scholar
  • 20 Scammell TE, Arrigoni E, Lipton JO. Neural Circuitry of Wakefulness and Sleep. Neuron 2017; 93: 747-765
    CrossrefPubMedGoogle Scholar
  • 21 Tafti M, Hor H, Dauvilliers Y. et al. DQB1 locus alone explains most of the risk and protection in narcolepsy with cataplexy in Europe. Sleep 2014; 37: 19-25
    CrossrefPubMedGoogle Scholar
  • 22 Mignot E, Thorsby E. Narcolepsy and the HLA system. N Engl J Med 2001; 344: 692
    CrossrefPubMedGoogle Scholar
  • 23 Mignot E. Genetic and familial aspects of narcolepsy. Neurology 1998; 50: S16-22
    CrossrefPubMedGoogle Scholar
  • 24 Mignot E, Lammers GJ, Ripley B. et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-1562
    CrossrefPubMedGoogle Scholar
  • 25 Lin L, Hungs M, Mignot E. Narcolepsy and the HLA region. J Neuroimmunol 2001; 117: 9-20
    CrossrefPubMedGoogle Scholar
  • 26 Baumann CR, Mignot E, Lammers GJ. et al. Challenges in diagnosing narcolepsy without cataplexy: a consensus statement. Sleep 2014; 37: 1035-1042
    CrossrefPubMedGoogle Scholar
  • 27 Nishino S, Kanbayashi T. Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system. Sleep Med Rev 2005; 9: 269-310
    CrossrefPubMedGoogle Scholar
  • 28 Kallweit U, Bassetti CLA, Oberholzer M. et al. Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis: six new cases and a literature review. J Neurol 2018; 265: 2071-2078
    CrossrefPubMedGoogle Scholar
  • 29 Omokawa M, Ayabe T, Nagai T. et al. Decline of CSF orexin (hypocretin) levels in Prader-Willi syndrome. Am J Med Genet A 2016; 170A: 1181-1186
    CrossrefPubMedGoogle Scholar
  • 30 Nevsimalova S, Malinova V. Cataplexy and sleep disorders in Niemann-Pick type C disease. Curr Neurol Neurosci Rep 2015; 15: 522
    CrossrefPubMedGoogle Scholar
  • 31 Littner MR, Kushida C, Wise M. et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005; 28: 113-121
    CrossrefPubMedGoogle Scholar
  • 32 Sateia MJ. International classification of sleep disorders-third edition: Highlights and modifications. Chest 2014; 146: 1387-1394
    CrossrefPubMedGoogle Scholar
  • 33 Mignot E, Lin L, Finn L. et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006; 129: 1609-1623
    CrossrefPubMedGoogle Scholar
  • 34 Lopez R, Doukkali A, Barateau L. et al. Test-retest reliability of the multiple sleep latency test in central disorders of hypersomnolence. Sleep 2017 40.
    Google Scholar
  • 35 Trotti LM, Staab BA, Rye DB. Test-retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia. J Clin Sleep Med 2013; 9: 789-795
    CrossrefPubMedGoogle Scholar
  • 36 Ripley B, Overeem S, Fujiki N. et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57: 2253-2258
    CrossrefPubMedGoogle Scholar
  • 37 Bargiotas P, Dietmann A, Haynes AG. et al. The Swiss Narcolepsy Scale (SNS) and its short form (sSNS) for the discrimination of narcolepsy in patients with hypersomnolence: A cohort study based on the Bern sleep-wake database. J Neurol 2019; 266: 2137-2143
    CrossrefPubMedGoogle Scholar
  • 38 Pizza F, Jaussent I, Lopez R. et al. Car crashes and central disorders of hypersomnolence: a French study. PLoS One 2015; 10: e0129386
    CrossrefPubMedGoogle Scholar
  • 39 [Anonym]. Begutachtungsleitlinien zur Kraftfahreignung vom 27. Januar 2014 (Verkehrsblatt S. 110), Fassung vom 28.10.2019 (Verkehrsblatt S. 775), in Kraft getreten am 31.12.2019 mit der Vierzehnten Verordnung zur Änderung der Fahrerlaubnis-Verordnung und anderer straßenverkehrsrechtlicher Vorschriften. In. Bundesgesetzblatt Teil I Nr. 52 vom 30. Dezember 2019.
    Google Scholar
  • 40 Scammell TE. Narcolepsy. N Engl J Med 2015; 373: 2654-2662
    CrossrefPubMedGoogle Scholar
  • 41 Kallweit U, Bassetti CL. Pharmacological management of narcolepsy with and without cataplexy. Expert Opin Pharmacother 2017; 18: 809-817
    CrossrefPubMedGoogle Scholar
  • 42 [Anonym]. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy multicenter study group. Ann Neurol 1998; 43: 88-97
    CrossrefPubMedGoogle Scholar
  • 43 [Anonym]. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy multicenter study group. Neurology 2000; 54: 1166-1175
    CrossrefPubMedGoogle Scholar
  • 44 Markham A. Solriamfetol: First Global Approval. Drugs 2019; 79: 785-790
    CrossrefPubMedGoogle Scholar
  • 45 Dauvilliers Y, Arnulf I, Szakacs Z. et al. Long-term use of pitolisant to treat patients with narcolepsy: harmony III study. Sleep 2019 42.
    Google Scholar
  • 46 Szakacs Z, Dauvilliers Y, Mikhaylov V. et al. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: A randomised, double-blind, placebo-controlled trial. Lancet Neurol 2017; 16: 200-207
    CrossrefPubMedGoogle Scholar
  • 47 Group XIS. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy. J Clin Sleep Med 2005; 1: 391-397
    CrossrefPubMedGoogle Scholar
  • 48 [Anonym]. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002; 25: 42-49
    CrossrefPubMedGoogle Scholar
  • 49 Mamelak M, Black J, Montplaisir J. et al. A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy. Sleep 2004; 27: 1327-1334
    CrossrefPubMedGoogle Scholar
  • 50 [Anonym]. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 2003; 26: 31-35
    PubMedGoogle Scholar
  • 51 Parkes JD, Chen SY, Clift SJ. et al. The clinical diagnosis of the narcoleptic syndrome. J Sleep Res 1998; 7: 41-52
    CrossrefPubMedGoogle Scholar